Kappa-Opioid Receptor Blockade Ameliorates Obesity Caused by Estrogen Withdrawal via Promotion of Energy Expenditure through mTOR Pathway.
energy expenditure
estrogens
kappa-opioid
obesity
p70S6K
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
14 Mar 2022
14 Mar 2022
Historique:
received:
17
01
2022
revised:
25
02
2022
accepted:
11
03
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
9
4
2022
Statut:
epublish
Résumé
Weight gain is a hallmark of decreased estradiol (E2) levels because of menopause or following surgical ovariectomy (OVX) at younger ages. Of note, this weight gain tends to be around the abdomen, which is frequently associated with impaired metabolic homeostasis and greater cardiovascular risk in both rodents and humans. However, the molecular underpinnings and the neuronal basis for these effects remain to be elucidated. The aim of this study is to elucidate whether the kappa-opioid receptor (k-OR) system is involved in mediating body weight changes associated with E2 withdrawal. Here, we document that body weight gain induced by OVX occurs, at least partially, in a k-OR dependent manner, by modulation of energy expenditure independently of food intake as assessed in Oprk1-/-global KO mice. These effects were also observed following central pharmacological blockade of the k-OR system using the k-OR-selective antagonist PF-04455242 in wild type mice, in which we also observed a decrease in OVX-induced weight gain associated with increased UCP1 positive immunostaining in brown adipose tissue (BAT) and browning of white adipose tissue (WAT). Remarkably, the hypothalamic mTOR pathway plays an important role in regulating weight gain and adiposity in OVX mice. These findings will help to define new therapies to manage metabolic disorders associated with low/null E2 levels based on the modulation of central k-OR signaling.
Identifiants
pubmed: 35328539
pii: ijms23063118
doi: 10.3390/ijms23063118
pmc: PMC8953356
pii:
doi:
Substances chimiques
Estrogens
0
Receptors, Opioid, kappa
0
MTOR protein, human
EC 2.7.1.1
TOR Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Proc Natl Acad Sci U S A. 2012 Nov 27;109(48):19846-51
pubmed: 23150555
Cell Metab. 2011 Oct 5;14(4):453-65
pubmed: 21982706
Am J Nucl Med Mol Imaging. 2016 Aug 20;6(4):205-14
pubmed: 27648372
Cell Metab. 2008 Dec;8(6):459-67
pubmed: 19041762
Am J Physiol Endocrinol Metab. 2008 May;294(5):E817-26
pubmed: 18334610
Curr Biol. 2019 Dec 16;29(24):4291-4299.e4
pubmed: 31786059
Front Neurosci. 2015 Dec 16;9:466
pubmed: 26733781
Mol Metab. 2013 Jun 04;2(3):227-42
pubmed: 24049737
Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2501-6
pubmed: 17284595
Cold Spring Harb Protoc. 2014 Jun 02;2014(6):655-8
pubmed: 24890205
Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12729-34
pubmed: 11070086
Cell Rep. 2018 Oct 9;25(2):413-423.e5
pubmed: 30304681
Cell Metab. 2014 Jul 1;20(1):41-53
pubmed: 24856932
Cell Cycle. 2017 Mar 19;16(6):493-494
pubmed: 28135904
Endocrinology. 2016 Jul;157(7):2735-49
pubmed: 27183316
Front Neuroendocrinol. 2013 Aug;34(3):211-27
pubmed: 23872331
Gen Comp Endocrinol. 2010 May 1;166(3):520-8
pubmed: 20067798
Endocrinology. 2013 Sep;154(9):2992-3000
pubmed: 23782940
Neuropsychopharmacology. 2019 Apr;44(5):939-949
pubmed: 30082888
Endocrinology. 1995 Apr;136(4):1589-94
pubmed: 7895668
Neuropharmacology. 2018 Mar 1;130:62-70
pubmed: 29191753
FASEB J. 2012 Aug;26(8):3483-92
pubmed: 22593549
Hepatology. 2016 Oct;64(4):1086-104
pubmed: 27387967
Endocrinology. 2017 May 1;158(5):1095-1105
pubmed: 28323912
Endocrinology. 1990 Feb;126(2):804-8
pubmed: 2153527
Best Pract Res Clin Endocrinol Metab. 2016 Aug;30(4):527-536
pubmed: 27697213
Nat Commun. 2019 Sep 6;10(1):4037
pubmed: 31492869
Gastroenterology. 2013 Mar;144(3):636-649.e6
pubmed: 23142626
Am J Physiol Endocrinol Metab. 2007 Nov;293(5):E1265-73
pubmed: 17726140
Endocr Rev. 2013 Jun;34(3):309-38
pubmed: 23460719
Cell Rep. 2013 Dec 12;5(5):1196-203
pubmed: 24290753
Am J Physiol Endocrinol Metab. 2010 Sep;299(3):E341-50
pubmed: 20501877
FASEB J. 2010 Apr;24(4):1151-9
pubmed: 19917675
J Comp Neurol. 1997 Dec 1;388(4):507-25
pubmed: 9388012
J Neurosci. 2001 Aug 1;21(15):5723-9
pubmed: 11466444
ACS Chem Neurosci. 2019 Aug 21;10(8):3590-3600
pubmed: 31313902
Cell Metab. 2016 Jun 14;23(6):1200-1206
pubmed: 27238638
Curr Biol. 2019 Dec 16;29(24):R1323-R1325
pubmed: 31846684
Neuropsychopharmacology. 2013 Jun;38(7):1296-307
pubmed: 23348063
Nutr Metab (Lond). 2019 Nov 6;16:74
pubmed: 31708995
Nat Metab. 2019 Aug;1(8):811-829
pubmed: 31579887
Nat Rev Endocrinol. 2017 Jun;13(6):352-364
pubmed: 28304393
Endocrinology. 2009 May;150(5):2161-8
pubmed: 19179442
J Endocrinol. 2018 Sep;238(3):177-186
pubmed: 29914932
Nat Rev Endocrinol. 2017 Jan;13(1):26-35
pubmed: 27616452
Trends Endocrinol Metab. 2015 Aug;26(8):411-21
pubmed: 26126705
Diabetes. 2016 Feb;65(2):421-32
pubmed: 26566631
Physiol Behav. 1979 Mar;22(3):583-93
pubmed: 379889
Climacteric. 2012 Oct;15(5):419-29
pubmed: 22978257
Nat Med. 2012 Dec;18(12):1847-56
pubmed: 23142820
Endocrinology. 2009 Nov;150(11):5016-26
pubmed: 19734277
Mol Pharmacol. 2011 Nov;80(5):920-9
pubmed: 21832171
Nat Rev Endocrinol. 2016 Jul;12(7):421-32
pubmed: 27199291